efile Public Visual Render
ObjectId: 201923169349306077 - Submission: 2019-11-12
TIN: 91-1157127
Form
990
Department of the Treasury
Internal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
Do not enter social security numbers on this form as it may be made public.
Go to
www.irs.gov/Form990
for instructions and the latest information.
OMB No. 1545-0047
20
18
Open to Public Inspection
A
For the 2019 calendar year, or tax year beginning
01-01-2018
, and ending
12-31-2018
B
Check if applicable:
Address change
Name change
Initial return
Final return/terminated
Amended return
Application pending
C
Name of organization
PATH
Doing business as
Number and street (or P.O. box if mail is not delivered to street address)
2201 WESTLAKE AVENUE NO 200
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
SEATTLE
,
WA
98121
D Employer identification number
91-1157127
E Telephone number
(206) 285-3500
G
Gross receipts $
388,448,491
F
Name and address of principal officer:
BRIAN NEVILLE
2201 WESTLAKE AVENUE NO 200
SEATTLE
,
WA
98121
I
Tax-exempt status:
501(c)(3)
501(c)
(
)
(insert no.)
4947(a)(1)
or
527
J
Website:
WWW.PATH.ORG
H(a)
Is this a group return for
subordinates?
Yes
No
H(b)
Are all subordinates
included?
Yes
No
If "No," attach a list. (see instructions)
H(c)
Group exemption number
K
Form of organization:
Corporation
Trust
Association
Other
L
Year of formation:
1981
M
State of legal domicile:
WA
Part I
Summary
1
Briefly describe the organization’s mission or most significant activities:
SEE PART III, LINE 1.
2
Check this box
3
Number of voting members of the governing body (
Part VI
, line 1a)
........
3
14
4
Number of independent voting members of the governing body (
Part VI
, line 1b)
.....
4
14
5
Total number of individuals employed in calendar year 2018 (
Part V
, line 2a)
......
5
787
6
Total number of volunteers (estimate if necessary)
.............
6
0
7a
Total unrelated business revenue from
Part VIII
, column (C), line 12
........
7a
0
b
Net unrelated business taxable income from Form 990-T, line 34
.........
7b
547,406
Prior Year
Current Year
8
Contributions and grants (
Part VIII
, line 1h)
.........
347,844,394
305,315,221
9
Program service revenue (
Part VIII
, line 2g)
.........
41,949
1,500
10
Investment income (
Part VIII
, column (A), lines 3, 4, and 7d )
....
2,168,657
3,037,130
11
Other revenue (
Part VIII
, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)
5,225,302
980,560
12
Total revenue—add lines 8 through 11 (must equal
Part VIII
, column (A), line 12)
355,280,302
309,334,411
13
Grants and similar amounts paid (
Part IX
, column (A), lines 1–3 )
...
66,754,537
62,762,146
14
Benefits paid to or for members (
Part IX
, column (A), line 4)
.....
0
0
15
Salaries, other compensation, employee benefits (
Part IX
, column (A), lines 5–10)
136,040,867
139,545,675
16a
Professional fundraising fees (
Part IX
, column (A), line 11e)
.....
0
0
b
Total fundraising expenses (
Part IX
, column (D), line 25)
3,186,635
17
Other expenses (
Part IX
, column (A), lines 11a–11d, 11f–24e)
....
126,837,131
110,458,648
18
Total expenses. Add lines 13–17 (must equal
Part IX
, column (A), line 25)
329,632,535
312,766,469
19
Revenue less expenses. Subtract line 18 from line 12
.......
25,647,767
-3,432,058
Beginning of Current Year
End of Year
20
Total assets (
Part X
, line 16)
.............
467,947,698
237,501,233
21
Total liabilities (
Part X
, line 26)
.............
50,797,492
202,931,874
22
Net assets or fund balances. Subtract line 21 from line 20
.....
417,150,206
34,569,359
Part II
Signature Block
Sign Here
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
2019-11-12
Signature of officer
Date
BRIAN NEVILLE
CHIEF OF ACCOUNTING
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
Check
if
self-employed
PTIN
P00288314
Firm's name
GELMAN ROSENBERG & FREEDMAN
Firm's EIN
52-1392008
Firm's address
4550 MONTGOMERY AVE SUITE 800N
BETHESDA
,
MD
208142930
Phone no.
(301) 951-9090
May the IRS discuss this return with the preparer shown above? (see instructions)
..........
Yes
No
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y
Form
990
(2018)
Page 2
Form 990 (2018)
Page
2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this
Part III
..............
1
Briefly describe the organization’s mission:
PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ?
.....................
Yes
No
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services?
...........................
Yes
No
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a
(Code:
) (Expenses $
128,263,294
including grants of $
15,311,912
) (Revenue $
1,500
)
GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION BRINGS TOGETHER OUR SIGNIFICANT COUNTRY EXPERIENCE AND DEEP TECHNICAL EXPERTISE TO FACILITATE THE ORGANIZATION'S ABILITY TO ACHIEVE IMPACT THROUGH INNOVATIVE APPROACHES AND SOLUTIONS. THIS DIVISION MANAGES PATH'S PRESENCE IN COUNTRY OFFICES AND IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; NONCOMMUNICABLE DISEASES; HEALTH SYSTEMS INNOVATION AND DELIVERY; AND DIGITAL HEALTH SOLUTIONS.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE THAT OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. APPROACHES PIONEERED BY PATH HAVE CONTRIBUTED TO REMARKABLE PROGRESS TOWARD CONTROLLING AND ELIMINATING MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2018, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA AS THEY STRIVE TO ACHIEVE THEIR MALARIA ELIMINATION GOALS. WE HELPED BY SCALING UP PREVENTION AND TREATMENT, EVALUATING SENSITIVE DIAGNOSTIC TOOLS, ESTABLISHING RAPID REPORTING SYSTEMS, AND SUPPORTING POPULATION-WIDE, DRUG-BASED STRATEGIES, SUCH AS MASS DRUG ADMINISTRATION. THROUGH OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES, PATH ASSISTED THE GOVERNMENT OF ZAMBIA IN REACHING ITS GOALS FOR ELIMINATING LOCAL MALARIA INFECTION AND DISEASE. THIS WORK FOCUSED ON BEDNETS, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, CASE MANAGEMENT, SURVEILLANCE, AND MONITORING & EVALUATION. THE PROGRAM'S GEOGRAPHIC FOCUS IS ON PROVINCES WITH THE HIGHEST MALARIA PREVALENCE AMONG CHILDREN.PATH ALSO WORKED TO IMPROVE DATA FOR MALARIA CONTROL DECISION-MAKING AND SURVEILLANCE. IN ZAMBIA, FOR EXAMPLE, THE VISUALIZE NO MALARIA PROJECT-A GROUNDBREAKING PARTNERSHIP WITH A SEATTLE-BASED SOFTWARE COMPANY AND A COALITION OF OTHER TECHNOLOGY COMPANIES-CONTINUED TO EXPAND. THIS PROJECT EQUIPS HEALTH WORKERS AND OFFICIALS WITH REAL-TIME DATA VISUALIZATION TOOLS TO SEE WHERE MALARIA IS APPEARING SO THEY CAN DEPLOY RESOURCES TO HALT ITS SPREAD. IN WESTERN KENYA, PATH ASSESSED THE POTENTIAL CONTRIBUTION OF MALARIA TESTING DATA FROM PREGNANT WOMEN ATTENDING ANTENATAL CLINICS AS A MEANS TO BOLSTER SURVEILLANCE.IN 2018, PATH ALSO WORKED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S MALARIA VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. VACCINATIONS ARE DUE TO BEGIN IN 2019. PATH CONTINUED TO DEVELOP AND EVALUATE NEW VECTOR-CONTROL TOOLS SUCH AS NEXT-GENERATION INDOOR RESIDUAL SPRAYING (IN PARTNERSHIP WITH THE INNOVATIVE VECTOR CONTROL CONSORTIUM, THE US PRESIDENT'S MALARIA INITIATIVE, ABT ASSOCIATES, AND THE GLOBAL FUND). THIS WORK IS GENERATING EVIDENCE TO SUPPORT TIMELY DECISION-MAKING AROUND THE ADOPTION OF NEW INSECTICIDES THAT ARE EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. PATH ALSO LED EVALUATION AND DATA-FOR-DECISION-MAKING ACTIVITIES UNDER VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP VECTOR-CONTROL PARTNERSHIP. IN ADDITION, WE DIRECTED EVIDENCE-GENERATION ACTIVITIES UNDER THE NEW NETS PROJECT, FUNDED BY UNITAID AND THE GLOBAL FUND, TO HELP SCALE UP ACCESS TO AND USE OF NEW LONG-LASTING INSECTICIDE-TREATED NETS.TO ADDRESS THE TWIN THREATS OF INSECTICIDE RESISTANCE AND OUTDOOR BITING BY MOSQUITOES, PATH CONTINUED THE DEVELOPMENT AND EVALUATION OF ATTRACTIVE TARGETED SUGAR BAITS, WHICH PRESENT A SUGAR MEAL FOR MOSQUITOES THAT IS LACED WITH AN INSECTICIDE. PATH ALSO SUPPORTED THE DEVELOPMENT OF A NEW, HIGHLY SENSITIVE RAPID DIAGNOSTIC TEST THAT OFFERS A GREATER THAN TENFOLD IMPROVEMENT IN DETECTION OF THE MOST COMMON MALARIA PARASITE. FINALLY, WE ADVANCED WORK ON A POINT-OF-CARE DIAGNOSTIC TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY, A CONDITION THAT CAN COMPLICATE MALARIA TREATMENT.IN PATH'S EFFORTS TO FIGHT NEGLECTED TROPICAL DISEASES, OUR WORK INCLUDES DEFINING PRODUCT NEEDS; DEVELOPING TARGET PRODUCT PROFILES; ENGAGING WITH STAKEHOLDERS; CONDUCTING LABORATORY AND FIELD TESTS AND EVALUATIONS; TRANSFERRING TECHNOLOGY AND SECURING MANUFACTURING, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS; COMMERCIALIZING PRODUCTS AND COLLATERAL; AND SUPPORTING PRODUCT LAUNCH. MUCH OF THIS WORK IS ACCOMPLISHED VIA PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION.HIV AND TUBERCULOSISPATH CONTINUED TO CONTRIBUTE TO HIV PREVENTION AND EPIDEMIC CONTROL IN 2018 BY FOCUSING PROGRAMMING ON THE KEY AND HIGH-PRIORITY POPULATIONS OF ADOLESCENT GIRLS AND YOUNG WOMEN, PEOPLE WITH BOTH HIV AND TUBERCULOSIS (TB), SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, AND TRANSGENDER INDIVIDUALS. WE ADVANCED PROGRAMMING ACROSS MULTIPLE TECHNOLOGY AND SERVICE DELIVERY PLATFORMS-FROM DEVICES, TOOLS, AND DIAGNOSTICS TO SERVICE DELIVERY INNOVATIONS AND ADVOCACY. PATH'S WORK IN DIAGNOSTICS FOCUSED ON FILLING GAPS IN FOUR CRITICAL AREAS: SELF-TESTING, EARLY INFANT DIAGNOSIS, TB DETECTION AMONG PEOPLE LIVING WITH HIV, AND VIRAL LOAD DETECTION. WE FOCUSED ON UNDERSTANDING THE BARRIERS THAT RESTRICT ACCESS TO HIGH-QUALITY DIAGNOSTICS AND ADVANCING NEW PRODUCTS TO OVERCOME THESE OBSTACLES. TO INFORM DESIGN AND DELIVERY OF NEXT-GENERATION HIV SELF-TESTS, PATH EMPLOYED USER-CENTERED DESIGN METHODOLOGIES TO CREATE USER PERSONAS REPRESENTING KEY POPULATIONS. PATH ALSO WORKED TO EVALUATE AND ADVANCE DEVICES TO PROVIDE LONG-TERM ANTIRETROVIRAL DELIVERY FOR PRE-EXPOSURE PROPHYLAXIS (PREP) AND HIV TREATMENT. THESE DEVICES INCLUDE MICROARRAY PATCHES FOR TRANSDERMAL DELIVERY AND AN APPLICATOR TO SUBCUTANEOUSLY INSERT BIODEGRADABLE IMPLANTS. WE ALSO WORKED ON A PEDIATRIC-FRIENDLY DOSAGE FORM OF ANTIRETROVIRAL DRUGS, USING OUR FAST-DISSOLVING TABLET TECHNOLOGY.THROUGH THE AIDS, POPULATION, AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS PROJECT), PATH HELPED TO INTEGRATE HEALTH SERVICES IN WESTERN KENYA AND ENABLE MORE PEOPLE TO ACCESS A GREATER SPECTRUM OF SERVICES. SINCE 2011, THE PATH-LED TEAM HAS BUILT THE CAPACITY OF HEALTH CARE WORKERS AND FACILITIES TO DELIVER HIGH-QUALITY SERVICES FOR HIV, TB, SEXUAL AND REPRODUCTIVE HEALTH, AND ADOLESCENT HEALTH; STRENGTHENED LINKAGES BETWEEN HEALTH FACILITIES AND COMMUNITIES TO EXPEDITE ACCESS TO HIV CARE AND TREATMENT; ESTABLISHED COMMUNITY SUPPORT SYSTEMS FOR PEOPLE LIVING WITH HIV AND THEIR FAMILIES; AND EMPOWERED AND MOBILIZED COMMUNITIES AROUND HIV PREVENTION AND OUTREACH.IN 2018, PATH TRANSITIONED HIV ACTIVITIES IN KENYA'S FORMER NYANZA PROVINCE TO USAID'S PATH-LED AFYA ZIWANI PROJECT, WHILE CONTINUING HIV AND TB SERVICE DELIVERY IN THE FORMER WESTERN PROVINCE THROUGH APHIAPLUS. WITH FUNDING FROM THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF DREAMS INITIATIVE, APHIAPLUS AND THE AFYA ZIWANI PROJECT INTENSIFIED EFFORTS TO REACH MORE THAN 77,500 ADOLESCENT GIRLS AND YOUNG WOMEN IN KENYA WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES. THIS WORK INCLUDED THE CREATION OF MORE THAN 200 SAFE SPACES AND IMPROVED ACCESS TO YOUTH-FRIENDLY FAMILY PLANNING, HIV, AND GENDER-BASED VIOLENCE SERVICES. IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), PATH CONTINUED TO LEAD USAID-FUNDED EFFORTS TO IMPROVE HIV/AIDS SERVICES. IN 2018, THIS WORK FOCUSED ON TWO HIGH-PREVALENCE PROVINCES UNDER THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA AND LUALABA. PATH PROVIDED TECHNICAL ASSISTANCE TO 162 HEALTH FACILITIES, 18 HEALTH ZONES, AND 5 NONGOVERNMENTAL ORGANIZATIONS TO INCREASE TARGETED TESTING EFFORTS, ENROLL ALL IDENTIFIED HIV-POSITIVE INDIVIDUALS ON TREATMENT, SCALE UP VIRAL LOAD TESTING, AND ROLL OUT DIFFERENTIATED CARE MODELS TO IMPROVE RETENTION IN TREATMENT. AT THE END OF DECEMBER 2018, PATH WAS SUPPORTING MORE THAN 33,000 INDIVIDUALS IN THE DRC ON ANTIRETROVIRAL THERAPY.
4b
(Code:
) (Expenses $
88,257,285
including grants of $
37,275,906
) (Revenue $
)
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES GLOBALLY AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATHS AND DISEASES WORLDWIDE.FOR EXAMPLE, IN 2018 WE CONTINUED TO PARTNER WITH COUNTRIES TO EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINE, WHICH PATH HELPED SHEPHERD THROUGH THE GLOBAL REGULATORY PROCESS AND SCALE UP. WITH SUPPORT FROM PATH, THE GOVERNMENT OF INDONESIA LAUNCHED JE VACCINATION CAMPAIGNS IN THE PROVINCE OF BALI. PATH ALSO PROVIDED TECHNICAL ASSISTANCE IN THE LEAD-UP TO JE VACCINATION CAMPAIGNS IN SELECT, HIGH-RISK REGIONS IN THE PHILIPPINES.IN 2018, WE CONTINUED A PHASE 2 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS VACCINE IN YOUNG CHILDREN IN MALI. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A VACCINE AGAINST MENINGOCOCCAL MENINGITIS SEROGROUP A THAT WAS LICENSED AND INTRODUCED IN 2010. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. THE VACCINE IS DESIGNED FOR USE IN THE AFRICAN "MENINGITIS BELT" REGION AND WILL BE THE FIRST VACCINE TO TARGET SEROGROUP X. TO PREVENT MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2018, PATH CONTINUED TO WORK WITH WHO AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. WITH PARTNERS, PATH CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. FIELD TESTING OF THE DELAYED FRACTIONAL DOSE REGIMEN BEGAN AT A RESEARCH CENTER IN KENYA IN 2018.PATH'S DEFEAT DIARRHEAL DISEASE INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ONGOING WORK TO GENERATE INVESTMENTS IN ROTAVIRUS, ENTEROTOXIGENIC ESCHERICHIA COLI, AND SHIGELLA VACCINES WITHIN THE CONTEXT OF AN INTEGRATED PREVENTION AND TREATMENT APPROACH. THE PROJECT RECEIVED STANDALONE FUNDING IN LATE 2018 TO CONTINUE EDUCATING OUR TARGET AUDIENCES ON THE LIFELONG CONSEQUENCES OF REPEATED INFECTIONS. IN 2018, PATH ALSO HELPED INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ENTERIC VACCINES, INCLUDING THE NEWLY WHO-PREQUALIFIED ROTAVAC AND ROTASIIL ROTAVIRUS VACCINES AND TYPBAR-TCV TYPHOID CONJUGATE VACCINE. PATH LED AND/OR SUPPORTED ONGOING PHASE 4 CLINICAL TRIALS, CONDUCTED VACCINE IMPACT AND COST-EFFECTIVENESS ANALYSES, AND DISSEMINATED EVIDENCE THROUGH ADVOCACY AND COMMUNICATIONS TO INFORM COUNTRY DECISION-MAKING AROUND VACCINE INTRODUCTION AND PRODUCT SWITCHES.IN 2018, PATH CONTINUED TO SUPPORT SOUTH AFRICAN VACCINE MANUFACTURER THE BIOVAC INSTITUTE IN PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. THE INTENDED VACCINE POPULATION IS PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. ALSO IN 2018, PATH CONTINUED A PROJECT TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE AND SYNTHESIZE EXISTING EVIDENCE AND EVALUATE NEW DATA ON THE POTENTIAL FOR SINGLE-DOSE HPV VACCINATION. ALTHOUGH MANY COUNTRIES HAVE INTRODUCED HPV VACCINES INTO THEIR NATIONAL IMMUNIZATION SCHEDULES, SOME LOW- AND LOWER-MIDDLE-INCOME COUNTRIES HAVE DELAYED INTRODUCTION BECAUSE OF FINANCIAL, LOGISTICAL, OR OTHER BARRIERS. FOR THESE COUNTRIES, A SINGLE-DOSE REGIMEN COULD ACCELERATE INTRODUCTION OF HPV VACCINES INTO NATIONAL IMMUNIZATION SCHEDULES.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS TO ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN LIVING IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. WE WORK TO ADVANCE THE MOST PROMISING SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO POLICY INTRODUCTION.IN 2018, IN COLLABORATION WITH PARTNERS, PATH CONTINUED TO ADVANCE A PORTFOLIO OF DRUG PROJECTS TO REDUCE THE GLOBAL BURDEN OF ENTERIC AND DIARRHEAL DISEASE AMONG YOUNG CHILDREN. FOR EXAMPLE, WE MADE SIGNIFICANT PROGRESS IN VALIDATING A NEW RESEARCH ASSESSMENT TOOL FOR ENVIRONMENTAL ENTERIC DYSFUNCTION (EED)-AN INTESTINAL DISORDER COMMON AMONG CHILDREN LIVING IN LOW-RESOURCE SETTINGS THAT IS ASSOCIATED WITH INCREASED RISK OF STUNTING, COGNITIVE DEFICITS, AND REDUCED RESPONSIVENESS TO ORAL VACCINES. THE TOOL IS DESIGNED TO MEASURE MULTIPLE BIOMARKERS, INCLUDING THOSE OF EED, SYSTEMIC INFLAMMATION, GROWTH HORMONE RESISTANCE, AND MICRONUTRIENTS, AND COULD BE AN ASSET FOR EED CLINICAL RESEARCH IN LOW-INCOME COUNTRIES. THE DIARRHEA INNOVATIONS GROUP (DIG), AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED ITS WORK TO IMPROVE COLLABORATION FOR DIARRHEAL DISEASE RESEARCH AND ACCELERATE PROGRESS THROUGH PARTNERSHIPS. IN NOVEMBER 2018, DIG MEMBERS PETITIONED WHO TO INCLUDE CO-PACKAGED ORAL REHYDRATION SOLUTION (ORS) AND ZINC IN ITS MODEL LIST OF ESSENTIAL MEDICINES. JOINT ADMINISTRATION OF ORS AND ZINC HAS LONG BEEN RECOMMENDED FOR MANAGEMENT OF PEDIATRIC DIARRHEA, YET NO FORMAL GUIDANCE ON CO-PACKAGED ORS-ZINC EXISTED, AND THE NUMBER OF CHILDREN WITH DIARRHEA RECEIVING THE OPTIMAL TREATMENT REMAINS UNACCEPTABLY LOW AT LESS THAN 7 PERCENT. ONCE ADOPTED BY WHO, THIS GLOBAL POLICY CHANGE WILL HELP PRIORITIZE BOTH ORS AND ZINC AS THE DIARRHEA MANAGEMENT STANDARD AT THE NATIONAL LEVEL, ULTIMATELY IMPROVING COVERAGE AND SAVING LIVES.ALSO IN 2018, WE CONTINUED OUR WORK TO DEVELOP NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, ONE OF THE KEY PATHOGENS RESPONSIBLE FOR DIARRHEAL MORBIDITY IN CHILDREN UNDER FIVE YEARS OF AGE. IN ADDITION, WE PREPARED FOR A STUDY TO TEST THE INVESTIGATIONAL NEW DRUG IOWH032 AS AN ANTISECRETORY THERAPY FOR THE TREATMENT OF CHOLERA.PARALLEL TO DRUG RESEARCH AND DEVELOPMENT, PATH CONTINUED OUR WORK TO ENSURE THAT ESSENTIAL MEDICINES ARE RELIABLY ACCESSIBLE TO THE PEOPLE WHO NEED THEM. OUR ACCESS TO ESSENTIAL MEDICINES INITIATIVE CARRIED OUT AN IN-DEPTH ANALYSIS OF THE WHO ESSENTIAL MEDICINES LISTS AND DEVELOPED A TOOL TO HELP IDENTIFY AND PRIORITIZE MEDICINES WITH SUBOPTIMAL ACCESS AND USE. THE TOOL IS DESIGNED TO HELP GLOBAL AND COUNTRY STAKEHOLDERS BETTER UNDERSTAND ACCESS GAPS AND THE HEALTH IMPACT POTENTIAL OF ESSENTIAL MEDICINES. THIS, IN TURN, CAN GUIDE DECISION-MAKING ON ACTIVITIES AND INVESTMENTS. IN 2018, WE INTRODUCED THE TOOL TO A NUMBER OF PARTNERS AND FUNDERS AND EXPLORED OPPORTUNITIES TO MAKE IT PUBLICLY AVAILABLE.
4c
(Code:
) (Expenses $
26,496,089
including grants of $
4,929,933
) (Revenue $
)
TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION BEGAN THE YEAR AS TECHNOLOGY DEVELOPMENT AND INTRODUCTION (TDI). AS SUCH, IT WAS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT DEVICES, TOOLS, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. IN JULY 2018, TDI GREW TO INCLUDE ADDITIONAL PROGRAMS-SUCH AS MARKET DYNAMICS, DIGITAL & DATA, AND MONITORING & EVALUATION-AND WAS RENAMED TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI).(CONTINUED ON SCHEDULE O)DEVICES AND TOOLSTHE DEVICES AND TOOLS PROGRAM WITHIN TAMI IS PATH'S INNOVATIVE PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.IN 2018, THE PROGRAM'S MILESTONES INCLUDED TRANSFERRING THE DESIGN OF THE BUBBLE CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE AND OXYGEN BLENDER TO A MANUFACTURER, BEGINNING FIELD EVALUATIONS FOR A FREEZE-SAFE VACCINE CARRIER IN NEPAL WITH A STUDY PARTNER, AND COMPLETING A PROGRAMMATIC AND HUMAN FACTORS EVALUATION OF THREE BLOW-FILL-SEAL VACCINE CONTAINERS IN AFRICA AND ASIA, AS WELL AS RECLASSIFICATION OF THE FEMALE CONDOM BY THE US FOOD & DRUG ADMINISTRATION FROM A CATEGORY III TO CATEGORY II MEDICAL DEVICE.STAFF PRODUCED 17 JOURNAL ARTICLES AND REPORTS ON RESEARCH FINDINGS, RANGING FROM ASSESSMENTS OF TECHNOLOGIES TO IMPROVE IMMUNIZATION TO EVALUATIONS OF NEONATAL RESUSCITATORS.DIAGNOSTICSPATH'S WORK TO ADVANCE ACCURATE DIAGNOSTIC TECHNOLOGIES THAT STRENGTHEN HEALTH EQUITY INCLUDES TOOLS TO DETECT AND MONITOR NEGLECTED TROPICAL DISEASES, MALARIA, HIV, POLIO, AND NONCOMMUNICABLE DISEASES.IN 2018, OUR PIONEERING WORK IN MALARIA DIAGNOSTICS INCLUDED DEVELOPING NEW TOOLS TO IMPROVE DETECTION OF THE MALARIA PARASITE AND TESTS TO GUIDE THE CLINICAL CARE OF PATIENTS. WITH OUR RESEARCH AND DEVELOPMENT PARTNERS, PATH ADVANCED SEVERAL POINT-OF-CARE TESTS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. THIS INCLUDED COMPLETING FIELD-BASED STUDIES OF A QUANTITATIVE BIOSENSOR AND FACILITATING A COMMUNITY OF PRACTICE FOR GLOBAL RESEARCHERS WORKING TO ADVANCE G6PD DIAGNOSTICS. PATH DEVELOPED GEODX, A COMPUTER PROGRAM THAT ESTIMATES THE PLASMODIUM VIVAX BURDEN PER HEALTH FACILITY, THE TOTAL QUANTITY OF G6PD TESTS THAT WOULD BE REQUIRED PER COUNTRY, AND THE ASSOCIATED COST. ADDITIONALLY, WE COMPLETED VALIDATION OF A MULTIPLEXED ARRAY THAT MEASURES MULTIPLE MALARIA ANTIGENS AT LOW CONCENTRATIONS TO SUPPORT THE DEVELOPMENT OF IMPROVED RAPID DIAGNOSTIC TESTS.WITH PARTNERS, PATH ESTABLISHED A BIOREPOSITORY TO SUPPORT THE DEVELOPMENT OF IMPROVED PREECLAMPSIA DIAGNOSTICS. ADDITIONALLY, PATH CREATED NEW TRAINING MATERIALS, INCLUDING A USER AID, TO SUPPORT OPERATIONS RESEARCH ON AN IMPROVED PREECLAMPSIA TEST.IN COLLABORATION WITH A PRIVATE-SECTOR PARTNER, PATH WORKED TO SIGNIFICANTLY LOWER THE PRICE PER ANALYTE FOR A MULTIPLEXED TOOL THAT DETECTS UP TO SEVEN NUTRITION- AND DISEASE-RELATED BIOMARKERS FOR POPULATION-BASED SURVEILLANCE OF MICRONUTRIENT DEFICIENCIES.FURTHER, PATH AND OUR PARTNERS CONDUCTED FIELD STUDIES AND MARKET RESEARCH TO ASSESS AND VALIDATE THE APPLICATION OF A BOVINE ESTRUS DETECTION TEST IN LOW- AND MIDDLE-INCOME COUNTRIES TO IMPROVE LIVELIHOODS AND NUTRITION. THE PRODUCT WAS LAUNCHED WITH DISTRIBUTION PARTNERS IN KENYA, TANZANIA, AND UGANDA.IMPACT LABSPATH'S IMPACT LABS IN INDIA, KENYA, AND SOUTH AFRICA HELP TO ADVANCE THE MOST PROMISING HEALTH TECHNOLOGIES. THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON INNOVATIVE PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. THROUGH OUR NETWORK OF IMPACT LABS, PATH CAN LEVERAGE WORLD-CLASS GLOBAL AND COUNTRY EXPERTISE TO ACCELERATE THE DEVELOPMENT AND INTRODUCTION OF SCALABLE DEVICES, TOOLS, AND DIAGNOSTICS FOR HEALTH. THE KENYA IMPACT LAB WAS IN NASCENT STAGES IN 2018; ACTIVITIES FOR INDIA AND SOUTH AFRICA ARE DESCRIBED BELOW. THE INDIA IMPACT LAB WAS OFFICIALLY LAUNCHED IN JANUARY 2018 IN PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI AS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY (MEDTECH) INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE-UP. IN JULY 2018, THE IMPACT LAB LAUNCHED A 12-MONTH INTENSIVE PROGRAM: SOCIAL ALPHA QUEST FOR HEALTHCARE INNOVATIONS. THE QUEST FEATURED A SYSTEMATIC, COHORT-BASED ENGAGEMENT MODEL WITH TEN SELECTED MEDTECH PRODUCT START-UPS. THE PROGRAM PROVIDED THE START-UPS WITH CONTEXTUAL SUPPORT, GUIDANCE, AND MENTORSHIP IN PRODUCT DEVELOPMENT, CLINICAL EVIDENCE GENERATION, REGULATIONS, QUALITY MANAGEMENT, MARKET UNDERSTANDING, AND PROCUREMENT CHANNELS. THE IMPACT LAB PARTNERED AND SIGNED MEMORANDUMS OF UNDERSTANDING WITH FIVE TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES TO CONDUCT JOINT PROGRAMS FOR THE DEVELOPMENT OF THE INNOVATION ECOSYSTEM. THE IMPACT LAB ALSO DELIVERED EIGHT CURATED AND FOCUSED KNOWLEDGE PLATFORMS (FOR EXAMPLE, WORKSHOPS, ROUNDTABLES, AND MENTOR MIXERS). FOR THESE, THE IMPACT LAB ENGAGED EXPERTS FROM NUMEROUS LARGE AND SMALL MEDTECH COMPANIES. IN 2018, 60 TO 100 START-UPS PARTICIPATED IN EACH KNOWLEDGE PLATFORM (PRODUCT DEVELOPMENT, LOCAL AND GLOBAL REGULATIONS, STANDARDS, TESTING AND CALIBRATIONS, CERTIFICATION, VENDOR MANAGEMENT, QUALITY MANAGEMENT, AND MARKET ENTRY ASPECTS)-ALL HIGHLY RELEVANT TO THE GROWTH OF MEDTECH START-UPS AND THE INNOVATION ECOSYSTEM.FOR THE SOUTH AFRICA IMPACT LAB, A PRIMARY FOCUS OF 2018 WAS TO RE-ENGAGE AND RE-AFFIRM PATH'S RELATIONSHIP WITH THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) AND COMMITMENT TO OUR JOINT GLOBAL HEALTH INNOVATION ACCELERATOR (GHIA) PARTNERSHIP. FOR EXAMPLE, PATH FACILITATED A WORKSHOP WITH THE SAMRC REGARDING KEY COMMERCIALIZATION AND MARKET DYNAMICS CONCEPTS. WE ALSO PROVIDED TECHNICAL ASSISTANCE TO THE SAMRC AND OTHER PARTNERS ON A SUCCESSFUL GRAND CHALLENGES CANADA APPLICATION FOR A MATERNAL HEALTH MEDICAL DEVICE. THESE AND OTHER ACTIVITIES WERE CONDUCTED UNDER A GRANT FROM THE BILL & MELINDA GATES FOUNDATION TO THE SAMRC. THE GRANT WAS AIMED AT BUILDING GHIA'S CAPACITY TO IMPROVE THE AFFORDABILITY AND AVAILABILITY OF HEALTH CARE SERVICES BY SUPPORTING THE DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL TECHNOLOGIES DESIGNED FOR RESOURCE-LIMITED SETTINGS IN SOUTH AFRICA AND BEYOND.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT AND INTRODUCTION. IT BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION, ALIGNS EXPERTISE ACROSS TEAMS, AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. IN 2018, OUR WORK FOCUSED ON ASSESSING MARKETS AND IMPROVING MARKET FUNCTIONING FOR MALARIA DRUGS AND DRUG INTERMEDIATES, MALARIA DIAGNOSTICS, OXYGEN THERAPY DEVICES, AND DEVICES FOR TREATMENT OF PRECANCEROUS CERVICAL LESIONS. THE MARKET DYNAMICS PROGRAM ALSO COLLABORATED WITH THE ADVOCACY AND PUBLIC POLICY TEAM TO STRENGTHEN MARKETS FOR MATERNAL AND NEWBORN HEALTH PRODUCTS THROUGH POLICY ADVOCACY.
(Code:
) (Expenses $
25,764,391
including grants of $
5,244,395
) (Revenue $
)
ADVOCACY AND PUBLIC POLICY:PATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, GLOBALLY WITH MULTILATERAL AGENCIES ENGAGED IN HEALTH POLICY AND PLANNING, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2018, PATH LED ADVOCACY EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES AND EUROPE FOR RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH SECURITY. ONE EXAMPLE OF OUR SUCCESS WAS PASSAGE OF TWO POLICIES IN THE UNITED STATES THAT SOLIDIFIED US GOVERNMENT SUPPORT FOR RESEARCH AND DEVELOPMENT IN ITS GLOBAL HEALTH PROGRAMS. THANKS IN PART TO PATH'S EFFORTS TO EDUCATE MEMBERS OF CONGRESS, US GOVERNMENT FUNDING WAS MAINTAINED OR INCREASED FOR MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH RESEARCH AND DEVELOPMENT PROGRAMS.WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS DURING 2018, IN KENYA, YEARS OF ADVOCACY BY PATH RESULTED IN PASSAGE OF THE FIRST COMPREHENSIVE POLICY THAT HARMONIZES DELIVERY OF HEALTH CARE FOR CHILDREN FROM BIRTH THROUGH ADOLESCENCE. IN THE DRC, A NATIONAL STRATEGY AND A SUBNATIONAL POLICY WERE ADOPTED TO PRIORITIZE ELIMINATION OF HUMAN AFRICAN TRYPANOSOMIASIS, ALSO KNOWN AS SLEEPING SICKNESS. IN SOUTH AFRICA, PATH'S ADVOCACY INFLUENCED THE PRIORITIZATION OF RESEARCH AND DEVELOPMENT FOR HEALTH IN A NATIONAL POLICY FOR SCIENCE, TECHNOLOGY, AND INNOVATION. AND IN UGANDA, PATH SUCCESSFULLY ADVOCATED FOR FUNDS TO BE ALLOCATED FOR VACCINE DISTRIBUTION.SPECIAL INITIATIVES:PATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2018, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS: MALARIA; HIV/AIDS; MATERNAL, NEWBORN, AND CHILD HEALTH; NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; EPIDEMIC PREPAREDNESS AND RESPONSE/GLOBAL HEALTH SECURITY INNOVATION; AND HEALTH SYSTEMS STRENGTHENING/PRIMARY HEALTH CARE. EACH HEALTH IMPACT TEAM GOES THROUGH A STAGED PROCESS OF SCALE-UP AND GROWTH. THESE TEAMS DEVELOP AND EVOLVE STRATEGY, STRENGTHEN AND CONNECT PATH TALENT ACROSS GEOGRAPHIES AND PROGRAMS, AND FOCUS ON REVENUE GENERATION FOR PATH THROUGH EXTERNAL ENGAGEMENT AND POSITIONING WITH KEY PARTNERS AND DONORS.
4d
Other program services (Describe in Schedule O.)
(Expenses $
25,764,391
including grants of $
5,244,395
) (Revenue $
)
4e
Total program service expenses
268,781,059
Form
990
(2018)
Page 3
Form 990 (2018)
Page
3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)?
If "Yes," complete Schedule A
.....................
1
Yes
2
Is the organization required to complete
Schedule B, Schedule of Contributors
(see instructions)?
...
2
Yes
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office?
If "Yes," complete Schedule C,
Part I
.............
3
No
4
Section 501(c)(3) organizations.
Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year?
If "Yes," complete Schedule C,
Part II
..............
4
Yes
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Revenue Procedure 98-19?
If "Yes," complete Schedule C,
Part III
.................
5
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts?
If "Yes," complete Schedule D,
Part I
..................
6
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures?
If "Yes," complete Schedule D,
Part II
...
7
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets?
If "Yes," complete Schedule D,
Part III
.............
8
No
9
Did the organization report an amount in
Part X
, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in
Part X
; or provide credit counseling, debt management, credit repair, or debt negotiation services?
If "Yes," complete Schedule D,
Part IV
..............
9
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi-endowments?
If "Yes," complete Schedule D,
Part V
......
10
Yes
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable.
a
Did the organization report an amount for land, buildings, and equipment in
Part X
, line 10?
If "Yes," complete Schedule D,
Part VI
.
...................
11a
Yes
b
Did the organization report an amount for investments—other securities in
Part X
, line 12 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VII
.......
11b
No
c
Did the organization report an amount for investments—program related in
Part X
, line 13 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part VIII
.......
11c
No
d
Did the organization report an amount for other assets in
Part X
, line 15 that is 5% or more of its total assets reported in
Part X
, line 16?
If "Yes," complete Schedule D,
Part IX
............
11d
No
e
Did the organization report an amount for other liabilities in
Part X
, line 25?
If "Yes," complete Schedule D,
Part X
11e
No
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)?
If "Yes," complete Schedule D,
Part X
11f
No
12a
Did the organization obtain separate, independent audited financial statements for the tax year?
If "Yes," complete Schedule D, Parts XI and XII
.................
12a
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year?
If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional
12b
Yes
13
Is the organization a school described in section 170(b)(1)(A)(ii)?
If "Yes," complete Schedule E
13
No
14a
Did the organization maintain an office, employees, or agents outside of the United States?
.....
14a
Yes
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more?
If "Yes," complete Schedule F, Parts I and IV
.........
14b
Yes
15
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization?
If “Yes,” complete Schedule F, Parts II and IV
.....
15
Yes
16
Did the organization report on
Part IX
, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals?
If “Yes,” complete Schedule F, Parts III and IV
...
16
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on
Part IX
, column (A), lines 6 and 11e?
If "Yes," complete Schedule G,
Part I
(see instructions)
....
17
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on
Part VIII
, lines 1c and 8a?
If "Yes," complete Schedule G,
Part II
............
18
No
19
Did the organization report more than $15,000 of gross income from gaming activities on
Part VIII
, line 9a?
If "Yes," complete Schedule G,
Part III
...................
19
No
20a
Did the organization operate one or more hospital facilities?
If "Yes," complete Schedule H
....
20a
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on
Part IX
, column (A), line 1?
If “Yes,” complete Schedule I, Parts I and II
.....
21
Yes
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on
Part IX
, column (A), line 2?
If “Yes,” complete Schedule I, Parts I and III
........
22
Yes
Form
990
(2018)
Page 4
Form 990 (2018)
Page
4
Part IV
Checklist of Required Schedules
(continued)
Yes
No
23
Did the organization answer "Yes" to
Part VII
, Section A, line 3, 4, or 5 about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees?
If "Yes," complete Schedule J
.......................
23
Yes
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002?
If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a
...............
24a
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?
...
24b
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds?
...............
24c
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?
...
24d
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations.
Did the organization engage in an excess benefit transaction with a disqualified person during the year?
If "Yes," complete Schedule L,
Part I
............
25a
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ?
If "Yes," complete Schedule L,
Part I
...................
25b
No
26
Did the organization report any amount on
Part X
, line 5, 6, or 22 for receivables from or payables to any current or former officers, directors, trustees, key employees, highest compensated employees, or disqualified persons?
If "Yes," complete Schedule L,
Part II
................
26
No
27
Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity or family member of any of these persons?
If "Yes," complete Schedule L,
Part III
.........
27
No
28
Was the organization a party to a business transaction with one of the following parties (see Schedule L,
Part IV
instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, or key employee?
If "Yes," complete Schedule L,
Part IV
........................
28a
No
b
A family member of a current or former officer, director, trustee, or key employee?
If "Yes," complete Schedule L,
Part IV
.....................
28b
No
c
An entity of which a current or former officer, director, trustee, or key employee (or a family member thereof) was an officer, director, trustee, or direct or indirect owner?
If "Yes," complete Schedule L,
Part IV
...
28c
No
29
Did the organization receive more than $25,000 in non-cash contributions?
If "Yes," complete Schedule M
..
29
Yes
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions?
If "Yes," complete Schedule M
.............
30
No
31
Did the organization liquidate, terminate, or dissolve and cease operations?
If "Yes," complete Schedule N,
Part I
.
31
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets?
If "Yes," complete Schedule N,
Part II
...........
32
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3?
If "Yes," complete Schedule R,
Part I
........
33
No
34
Was the organization related to any tax-exempt or taxable entity?
If "Yes," complete Schedule R,
Part II
, III, or IV, and
Part V
, line 1
.........................
34
Yes
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
Yes
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)?
If "Yes," complete Schedule R,
Part V
, line 2
...
35b
Yes
36
Section 501(c)(3) organizations.
Did the organization make any transfers to an exempt non-charitable related organization?
If "Yes," complete Schedule R,
Part V
, line 2
.............
36
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes?
If "Yes," complete Schedule R,
Part VI
37
No
38
Did the organization complete Schedule O and provide explanations in Schedule O for
Part VI
, lines 11b and 19?
Note.
All Form 990 filers are required to complete Schedule O.
............
38
Yes
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this
Part V
...........
Yes
No
1a
Enter the number reported in Box 3 of Form 1096 Enter -0- if not applicable
..
1a
230
b
Enter the number of Forms W-2G included in line 1a.
Enter -0-
if not applicable
.
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?
..................
1c
Yes
Form
990
(2018)
Page 5
Form 990 (2018)
Page
5
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return
..................
2a
787
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note.
If the sum of lines 1a and 2a is greater than 250, you may be required to e-file (see instructions)
2b
Yes
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?
...
3a
Yes
b
If “Yes,” has it filed a Form 990-T for this year?
If “No” to line 3b, provide an explanation in Schedule O
...
3b
Yes
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?
..
4a
Yes
b
If "Yes," enter the name of the foreign country:
BE
,
CH
,
CG
,
ET
,
GH
,
IN
,
KE
,
BM
,
MZ
,
PE
,
SG
,
SF
,
SZ
,
TZ
,
UG
,
UK
,
UP
,
VM
,
ZA
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?
..
5a
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T?
............
5c
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions?
...
6a
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?
......................
6b
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor?
....................
7a
No
b
If "Yes," did the organization notify the donor of the value of the goods or services provided?
.....
7b
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?
.........................
7c
No
d
If "Yes," indicate the number of Forms 8282 filed during the year
....
7d
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?
..
7f
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required?
......................
7g
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C?
..........................
7h
8
Sponsoring organizations maintaining donor advised funds.
Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year?
.........................
8
9a
Did the sponsoring organization make any taxable distributions under section 4966?
...
9a
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?
...
9b
10
Section 501(c)(7) organizations.
Enter:
a
Initiation fees and capital contributions included on
Part VIII
, line 12
...
10a
b
Gross receipts, included on Form 990,
Part VIII
, line 12, for public use of club facilities
10b
11
Section 501(c)(12) organizations.
Enter:
a
Gross income from members or shareholders
.........
11a
b
Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them.)
..........
11b
12a
Section 4947(a)(1) non-exempt charitable trusts.
Is the organization filing Form 990 in lieu of Form 1041?
12a
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state?
Note.
See the instructions for additional information the organization must report on Schedule O.
13a
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans
....
13b
c
Enter the amount of reserves on hand
............
13c
14a
Did the organization receive any payments for indoor tanning services during the tax year?
.....
14a
No
b
If "Yes," has it filed a Form 720 to report these payments?
If "No," provide an explanation in Schedule O
..
14b
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year? If "Yes," see instructions and file Form 4720, Schedule N
.....
15
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income?
If "Yes," complete Form 4720, Schedule O
................
16
No
Form
990
(2018)
Page 6
Form 990 (2018)
Page
6
Part VI
Governance, Management, and Disclosure
For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines
8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this
Part VI
..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
14
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
14
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?
.................
2
No
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?
.
3
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed?
.
4
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets?
.
5
No
6
Did the organization have members or stockholders?
................
6
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body?
....................
7a
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body?
...................
7b
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body?
.......................
8a
Yes
b
Each committee with authority to act on behalf of the governing body?
............
8b
Yes
9
Is there any officer, director, trustee, or key employee listed in
Part VII
, Section A, who cannot be reached at the organization’s mailing address?
If "Yes," provide the names and addresses in Schedule O
.......
9
No
Section B. Policies
(
This Section B requests information about policies not required by the Internal Revenue Code.
)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates?
............
10a
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form?
............................
11a
Yes
b
Describe in Schedule O the process, if any, used by the organization to review this Form 990.
.....
12a
Did the organization have a written conflict of interest policy?
If "No," go to line 13
.......
12a
Yes
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts?
..........................
12b
Yes
c
Did the organization regularly and consistently monitor and enforce compliance with the policy?
If "Yes," describe in Schedule O how this was done
...................
12c
Yes
13
Did the organization have a written whistleblower policy?
...............
13
Yes
14
Did the organization have a written document retention and destruction policy?
.........
14
Yes
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official
...........
15a
Yes
b
Other officers or key employees of the organization
................
15b
Yes
If "Yes" to line 15a or 15b, describe the process in Schedule O (see instructions).
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?
......................
16a
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements?
............
16b
Section C. Disclosure
17
List the States with which a copy of this Form 990 is required to be filed
AL
,
AR
,
CA
,
CT
,
FL
,
IL
,
KS
,
KY
,
MA
,
MD
,
MI
,
MN
,
MS
,
NC
,
NH
,
NJ
,
NM
,
NY
,
OK
,
OR
,
PA
,
RI
,
SC
,
TN
,
UT
,
VA
,
WI
,
WV
18
Section 6104 requires an organization to make its Form 1023 (or 1024-A if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
Own website
Another's website
Upon request
Other (explain in Schedule O)
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
BRIAN NEVILLE CHIEF OF ACCOUNTING
2201 WESTLAKE AVE SUITE 200
SEATTLE
,
WA
98121
(206) 285-3500
Form
990
(2018)
Page 7
Form 990 (2018)
Page
7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this
Part VII
..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a
Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
List all of the organization’s
current
officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.
List all of the organization’s
current
key employees, if any. See instructions for definition of "key employee."
List the organization’s five
current
highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the
organization and any related organizations.
List all of the organization’s
former
officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.
List all of the organization’s
former directors or trustees
that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.
List persons in the following order: individual trustees or directors; institutional trustees; officers; key employees; highest
compensated employees; and former such persons.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and Title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W- 2/1099-MISC)
(E)
Reportable compensation from related organizations (W- 2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(1)
DAVID KING
......................................................................
CHAIR
2.00
.................
0.00
X
X
0
0
0
(2)
FELIX OLALE
......................................................................
VICE CHAIR
2.00
.................
0.00
X
X
0
0
0
(3)
YEHONG ZHANG
......................................................................
SECRETARY
2.00
.................
0.00
X
X
0
0
0
(4)
BRUCE MCNAMER
......................................................................
TREASURER
2.00
.................
0.00
X
X
0
0
0
(5)
DEAN ALLEN
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(6)
PEGGY JOHNSON
......................................................................
DIRECTOR (UNTIL 12/2018)
2.00
.................
0.00
X
0
0
0
(7)
GARY LOCKE
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(8)
JO ADDY
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(9)
IREENA VITTAL
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(10)
DEANNA OPPENHEIMER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(11)
JOEL HOLSINGER
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(12)
JOHN-ARNE ROTTINGEN
......................................................................
DIRECTOR
2.00
.................
0.00
X
0
0
0
(13)
HELENA WAYTH
......................................................................
DIRECTOR (BEGAN 6/2018)
2.00
.................
0.00
X
0
0
0
(14)
TSITSI MASIYIWA
......................................................................
DIRECTOR (UNTIL 3/2018)
2.00
.................
0.00
X
0
0
0
(15)
DENNIS SCHMATZ
......................................................................
DIRECTOR (UNTIL 3/2018)
2.00
.................
0.00
X
0
0
0
(16)
BETH GALETTI
......................................................................
DIRECTOR (BEGAN 12/2018)
2.00
.................
0.00
X
0
0
0
(17)
SANFORD MELZER
......................................................................
DIRECTOR (BEGAN 12/2018)
2.00
.................
0.00
X
0
0
0
Form
990
(2018)
Page 8
Form 990 (2018)
Page
8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
(continued)
(A)
Name and Title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W- 2/1099-MISC)
(E)
Reportable compensation from related organizations (W- 2/1099-MISC)
(F)
Estimated amount of other compensation from the organization and related organizations
(18)
STEPHEN B DAVIS
........................................................................
PRESIDENT AND CEO
38.00
.......................
2.00
X
665,877
0
62,780
(19)
OLIVIA D POLIUS
........................................................................
CHIEF FINANCIAL OFFICER
38.00
.......................
2.00
X
320,646
0
51,936
(20)
DANIEL LASTER
........................................................................
COO AND GENERAL COUNSEL
38.00
.......................
2.00
X
310,669
0
41,544
(21)
DAVID C KASLOW
........................................................................
VP - PRODUCT DEVELOPMENT
38.00
.......................
2.00
X
379,045
0
65,678
(22)
AMIE E BATSON
........................................................................
CHIEF STRATEGY OFFICER
39.00
.......................
1.00
X
378,150
0
22,577
(23)
KATHY CAHILL
........................................................................
VP - INTERNATIONAL DEVELOPMENT
40.00
.......................
0.00
X
345,013
0
26,620
(24)
DAVID W FLEMING
........................................................................
VP - PUBLIC HEALTH IMPACT
40.00
.......................
0.00
X
286,869
0
50,611
(25)
KATHRYN A O'DRISCOLL
........................................................................
CHIEF HUMAN RESOURCES OFFICER
40.00
.......................
0.00
X
279,820
0
27,714
(26)
ERICA J SESSLE
........................................................................
CHIEF OF STAFF
40.00
.......................
0.00
X
214,378
0
34,734
(27)
PRAVEEN RAJA
........................................................................
VP - TECH. DEV. & INNOVATION
40.00
.......................
0.00
X
333,003
0
31,412
(28)
ELAINE L GIBBONS
........................................................................
VP - GLOBAL ENGAGEMENT
40.00
.......................
0.00
X
265,826
0
65,813
(29)
JEFFREY D BERSON
........................................................................
ASSOCIATE DIRECTOR II
40.00
.......................
0.00
X
431,451
0
82,104
(30)
JAMES B MCKENNA
........................................................................
ASSOCIATE DIRECTOR II
40.00
.......................
0.00
X
396,308
0
75,232
(31)
TRAD M HATTON
........................................................................
CHIEF OF PARTY
40.00
.......................
0.00
X
321,206
0
48,784
(32)
BRUCE LAMONT INNIS
........................................................................
GLOBAL DISEASE AREA HEAD
40.00
.......................
0.00
X
311,376
0
26,645
(33)
JOHN O KONZ
........................................................................
GLOBAL INT. PORT/FIN MGMT. CVIA HEAD
40.00
.......................
0.00
X
299,215
0
64,603
1b
Sub-Total
................
c
Total from continuation sheets to
Part VII
, Section A
....
d
Total (add lines 1b and 1c)
...........
5,538,852
0
778,787
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization
340
Yes
No
3
Did the organization list any
former
officer, director or trustee, key employee, or highest compensated employee on line 1a?
If "Yes," complete Schedule J for such individual
..............
3
No
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000?
If "Yes," complete Schedule J for such
individual
...........................
4
Yes
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization?
If "Yes," complete Schedule J for such person
........
5
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
WIDENET CONSULTING GROUP LLC
2910 1ST AVE S 200
SEATTLE
,
WA
98134
CONSULTING
821,832
RANDSTAD INDIA PVT LTD
BLDG 9 STES 001/002 JASOLA
NEW DELHI
110025
IN
STAFFING SERVICES
715,744
WMBE PAYROLLING DBA TARGET CW
9475 CHESAPEAKE DRIVE
SAN DIEGO
,
CA
92123
GENERAL CONTRACTOR
564,411
SLALOM LLC
821 2ND AVE SUITE 1900
SEATTLE
,
WA
98104
CONSULTING
488,798
UNIFY CONSULTING LLC
1518 1ST AVE S STE 201
SEATTLE
,
WA
98134
CONSULTING
471,870
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization
51
Form
990
(2018)
Page 9
Form 990 (2018)
Page
9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this
Part VIII
.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
1a
Federated campaigns
..
1a
b
Membership dues
..
1b
c
Fundraising events
..
1c
d
Related organizations
1d
23,547,825
e
Government grants (contributions)
1e
112,897,926
f
All other contributions, gifts, grants, and similar amounts not included above
1f
168,869,470
g
Noncash contributions included
in lines 1a - 1f:$
259,914
h Total.
Add lines 1a-1f
.......
305,315,221
Business Code
2a
CONSULTANCIES
541900
1,500
1,500
b
c
d
e
f
All other program service revenue.
g
Total.
Add lines 2a–2f
....
1,500
3
Investment income (including dividends, interest, and other
similar amounts)
......
2,963,587
2,963,587
4
Income from investment of tax-exempt bond proceeds
5
Royalties
...........
(ii) Personal
(i) Real
6a
Gross rents
b
Less: rental expenses
c
Rental income or (loss)
d
Net rental income or (loss)
......
(ii) Other
(i) Securities
7a
Gross amount from sales of assets other than inventory
547,000
78,640,623
b
Less: cost or other basis and sales expenses
548,448
78,565,632
c
Gain or (loss)
-1,448
74,991
d
Net gain or (loss)
.....
73,543
73,543
8a
Gross income from fundraising events (not including $
of contributions reported on line 1c).
See
Part IV
, line 18
....
a
b
Less: direct expenses
...
b
c
Net income or (loss) from fundraising events
..
9a
Gross income from gaming activities.
See
Part IV
, line 19
...
a
b
Less: direct expenses
...
b
c
Net income or (loss) from gaming activities
..
10a
Gross sales of inventory, less
returns and allowances
..
a
b
Less: cost of goods sold
..
b
c
Net income or (loss) from sales of inventory
..
Business Code
Miscellaneous Revenue
11a
OTHER
900099
884,888
884,888
b
REIMBURSEMENTS
900099
95,672
95,672
c
d
All other revenue
....
e
Total.
Add lines 11a–11d
......
980,560
12
Total revenue.
See Instructions.
.....
309,334,411
1,500
0
4,017,690
Form
990
(2018)
Page 10
Form 990 (2018)
Page
10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).
Check if Schedule O contains a response or note to any line in this
Part IX
..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of
Part VIII
.
(A)
Total expenses
(B)
Program service
expenses
(C)
Management and
general expenses
(D)
Fundraising
expenses
1
Grants and other assistance to domestic organizations and domestic governments. See
Part IV
, line 21
20,575,733
20,575,733
2
Grants and other assistance to domestic individuals. See
Part IV
, line 22
9,313
9,313
3
Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See
Part IV
, line 15 and 16.
42,177,100
42,177,100
4
Benefits paid to or for members
5
Compensation of current officers, directors, trustees, and key employees
....
4,260,713
309,550
3,899,884
51,279
6
Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)
....
7
Other salaries and wages
102,073,963
74,628,680
26,015,749
1,429,534
8
Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)
....
10,426,617
10,426,617
9
Other employee benefits
.......
16,197,399
1,718,558
14,478,841
10
Payroll taxes
...........
6,586,983
3,707
6,583,276
11
Fees for services (non-employees):
a
Management
......
b
Legal
.........
394,432
171,093
223,097
242
c
Accounting
...........
331,915
33,164
298,751
d
Lobbying
...........
26,000
12,000
14,000
e
Professional fundraising services.
See
Part IV
, line 17
f
Investment management fees
......
207,672
207,672
g
Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)
20,027,156
13,543,689
6,447,874
35,593
12
Advertising and promotion
....
165,753
90,386
7,269
68,098
13
Office expenses
.......
8,810,563
7,390,713
1,376,052
43,798
14
Information technology
......
732,838
219,457
465,295
48,086
15
Royalties
..
381,001
202,061
178,910
30
16
Occupancy
...........
12,048,542
389,297
11,659,245
17
Travel
............
19,986,534
18,565,722
1,358,161
62,651
18
Payments of travel or entertainment expenses for any federal, state, or local public officials
.
19
Conferences, conventions, and meetings
....
8,333,110
8,022,756
269,979
40,375
20
Interest
...........
8,819
8,819
21
Payments to affiliates
.......
22
Depreciation, depletion, and amortization
..
2,974,173
3,101
2,971,072
23
Insurance
...
725,361
187,114
538,247
24
Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a
SUBCONTRACTS
24,705,297
23,525,529
1,132,123
47,645
b
EQUIP RENT & MAINT
3,443,347
2,203,342
1,236,793
3,212
c
LEAVE & BENS ALLOC
0
36,911,256
-37,679,297
768,041
d
FACILITIES ALLOC
0
12,623,474
-12,990,044
366,570
e
All other expenses
7,156,135
5,264,264
1,670,390
221,481
25
Total functional expenses.
Add lines 1 through 24e
312,766,469
268,781,059
40,798,775
3,186,635
26
Joint costs.
Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation.
Check here
if following SOP 98-2 (ASC 958-720).
Form
990
(2018)
Page 11
Form 990 (2018)
Page
11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this
Part IX
..............
(A)
Beginning of year
(B)
End of year
1
Cash–non-interest-bearing
........
3,035,980
1
7,576,050
2
Savings and temporary cash investments
.........
3,493,254
2
14,017,223
3
Pledges and grants receivable, net
......
254,454,281
3
35,571,476
4
Accounts receivable, net
.............
13,578,928
4
10,652,789
5
Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete
Part II
of Schedule L
.............
5
6
Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete
Part II
of Schedule L
..............
6
7
Notes and loans receivable, net
....
7
8
Inventories for sale or use
........
8
9
Prepaid expenses and deferred charges
......
4,753,758
9
5,307,245
10a
Land, buildings, and equipment: cost or other basis. Complete
Part VI
of Schedule D
10a
36,534,903
b
Less: accumulated depreciation
10b
25,486,998
11,878,205
10c
11,047,905
11
Investments—publicly traded securities
.
176,133,425
11
153,328,545
12
Investments—other securities. See
Part IV
, line 11
.....
12
13
Investments—program-related. See
Part IV
, line 11
..
13
14
Intangible assets
...............
14
15
Other assets. See
Part IV
, line 11
...........
619,867
15
0
16
Total assets.
Add lines 1 through 15 (must equal line 34)
...
467,947,698
16
237,501,233
17
Accounts payable and accrued expenses
.....
50,220,817
17
202,736,996
18
Grants payable
...
18
19
Deferred revenue
.........
19
20
Tax-exempt bond liabilities
.........
20
21
Escrow or custodial account liability.
Complete
Part IV
of Schedule D
21
22
Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
persons.
Complete
Part II
of Schedule L
..
22
23
Secured mortgages and notes payable to unrelated third parties
..
576,675
23
194,878
24
Unsecured notes and loans payable to unrelated third parties
..
24
25
Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24).
Complete
Part X
of Schedule D
25
26
Total liabilities.
Add lines 17 through 25
..
50,797,492
26
202,931,874
Organizations that follow SFAS 117 (ASC 958),
check here
and complete lines 27 through 29, and lines 33 and 34.
27
Unrestricted net assets
25,292,293
27
19,811,400
28
Temporarily restricted net assets
...........
388,460,737
28
14,757,959
29
Permanently restricted net assets
3,397,176
29
0
Organizations that do not follow SFAS 117 (ASC 958),
check here
and complete lines 30 through 34.
30
Capital stock or trust principal, or current funds
.....
30
31
Paid-in or capital surplus, or land, building or equipment fund
...
31
32
Retained earnings, endowment, accumulated income, or other funds
32
33
Total net assets or fund balances
...........
417,150,206
33
34,569,359
34
Total liabilities and net assets/fund balances
........
467,947,698
34
237,501,233
Form
990
(2018)
Page 12
Form 990 (2018)
Page
12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this
Part XI
..............
1
Total revenue (must equal
Part VIII
, column (A), line 12)
............
1
309,334,411
2
Total expenses (must equal
Part IX
, column (A), line 25)
............
2
312,766,469
3
Revenue less expenses. Subtract line 2 from line 1
..............
3
-3,432,058
4
Net assets or fund balances at beginning of year (must equal
Part X
, line 33, column (A))
..
4
417,150,206
5
Net unrealized gains (losses) on investments
...............
5
-393,146
6
Donated services and use of facilities
.................
6
7
Investment expenses
.....................
7
8
Prior period adjustments
.....................
8
9
Other changes in net assets or fund balances (explain in Schedule O)
........
9
-378,755,643
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal
Part X
, line 33, column (B))
10
34,569,359
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this
Part XII
.............
Yes
No
1
Accounting method used to prepare the Form 990:
Cash
Accrual
Other
If the organization changed its method of accounting from a prior year or checked "Other," explain in
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
Separate basis
Consolidated basis
Both consolidated and separate basis
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight
of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
b
If "Yes," did the organization undergo the required audit or audits?
If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
Form
990
(2018)
Form 990 (2018)
Additional Data
Software ID:
Software Version:
Form 990, Special Condition Description:
Special Condition Description